Sabine Bréchignac

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre et al. · Blood · 2018 · 420 citations · Full text

Medicine, Hematology, Oncology +15

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro et al. · Blood · 2016 · 276 citations · Full text

Medicine, Oncology, Hematologic Oncology +8

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Xavier Leleu, Michel Attal, Bertrand Arnulf et al. · Blood · 2013 · 208 citations

Medicine, Hematology, Pharmacotherapy +16

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

Christian Rosé, Sabine Bréchignac, D. Vassilief et al. · Leukemia Research · 2010 · 195 citations

Medicine, Hematology, Pharmacotherapy +11

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

Aurore Perrot, Valérie Lauwers‐Cancès, Elodie Tournay et al. · Journal of Clinical Oncology · 2019 · 179 citations · Full text

Medicine, Hematology, Oncology +16